{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:57:14Z","timestamp":1779926234724,"version":"3.53.1"},"reference-count":332,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Medulloblastoma is an aggressive central nervous system tumor affecting children more commonly between the ages of 5-9. It is usually localized in the cerebellum, leading to diffusion of tumor cells through the cerebrospinal fluid and metastases to other portions of the brain and spinal cord. Conventional treatment consists of surgical resection followed by adjuvant radiation and\/or chemotherapy. The side effects of these therapies are critical to consider, especially given that patients are in a distinct stage of their lives. In addition, the overall survival is not satisfactory ranging from 50-90% depending on the type of medulloblastoma. The molecular characterization has broadly subdivided medulloblastoma into four subgroups, and more recently, the single-cell transcriptomics studies have further identified several other subgroups. Important advances have been reported on the cell origin, their plasticity, heterogeneity of genetic and epigenetic alteration, and interaction with the immune and stromal components of the tumor microenvironment. Research studies on these key points are essential to make advances in planning the application of conventional therapies together with immunotherapies. Herein, we discuss the main advances recently obtained on medulloblastoma biology and immunotherapies. Overall, the biological and molecular features of medulloblastoma are briefly summarized to understand the reason for the application of the old and new immunotherapies. Immunotherapies considered include the identification of potential medulloblastoma neoantigens and tumor-associated antigens to generate antigen-specific T lymphocytes. The main antigens expressed by medulloblastoma cells and\/or by components of the tumor microenvironment will be considered as the molecular targets of antibodies, antibody derivatives, and chimeric antigen receptor effector cells to improve the conventional therapies. In the last portion of this review, the brief analysis of the activating and inhibiting receptors expressed by antitumor T, natural killer, and unconventional T cells can give new insights into the potential treatment of medulloblastoma.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1602930","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:27:51Z","timestamp":1751520471000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Medulloblastoma: biology and immunotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Alessandro","family":"Poggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Reggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena S.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizzia","family":"Raffaghello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui Cruz","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0922-z","article-title":"Molecular subgroups of medulloblastoma: The current consensus","volume":"123","author":"Taylor","year":"2012","journal-title":"Acta Neuropathologica"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02730","article-title":"Children\u2019s oncology group phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma","volume":"39","author":"Michalski","year":"2021","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0758","article-title":"Omission of upfront craniospinal irradiation in patients with low-risk WNT-pathway medulloblastoma is associated with unacceptably high risk of neuraxial failure","volume":"28","author":"Gupta","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa122","article-title":"Bridging the treatment gap in infant medulloblastoma: Molecularly informed outcomes of a globally feasible regimen","volume":"22","author":"Baroni","year":"2020","journal-title":"Neuro-Oncology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70867-1","article-title":"Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial","volume":"7","author":"Gajjar","year":"2006","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-025-02255-4","article-title":"The epigenetic hallmarks of immune cells in cancer","volume":"24","author":"Ji","year":"2025","journal-title":"Mol Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2025.02.005","article-title":"Inflammation and tumor immune escape in response to DNA damage","volume":"110","author":"Nihira","year":"2025","journal-title":"Semin Cancer Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1531592","article-title":"Neoantigens: new hope for cancer therapy","volume":"15","author":"Hu","year":"2025","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-024-01091-9","article-title":"Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment","volume":"25","author":"Baharom","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05593-1","article-title":"\u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects","volume":"613","author":"de Vries","year":"2023","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.02.013","article-title":"Sex hormones, the anticancer immune response, and therapeutic opportunities","volume":"43","author":"Conforti","year":"2025","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20231954","article-title":"Lymphatic transport in anti-tumor immunity and metastasis","volume":"222","author":"Sun","year":"2025","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2024.06.007","article-title":"Immune surveillance of senescence: potential application to age-related diseases","volume":"35","author":"Wang","year":"2025","journal-title":"Trends Cell Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12964-025-02033-1","article-title":"Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion","volume":"23","author":"Xia","year":"2025","journal-title":"Cell communication signaling: CCS"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/10732748251316604","article-title":"Macrophage polarisation in the tumour microenvironment: recent research advances and therapeutic potential of different macrophage reprogramming","volume":"32","author":"Guo","year":"2025","journal-title":"Cancer Control"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512053132327","article-title":"at.Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(90)90046-c","article-title":"An explanation of the variable clinical response to interleukin 2 and LAK cells","volume":"11","author":"Parmiani","year":"1990","journal-title":"Immunol Today"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.13.932","article-title":"Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response","volume":"83","author":"Aebersold","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/BF00205236","article-title":"Combined effects of interferon \u03b1 and interleukin 2 on the induction of a vascular leak syndrome in mice","volume":"28","author":"Puri","year":"1989","journal-title":"Cancer Immunol Immunotherapy"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19911115)68:10<2169::aid-cncr2820681014>3.0.co;2-f","article-title":"An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2","volume":"68","author":"Fujita","year":"1991","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191247","article-title":"Effects of interleukin-2 in immunostimulation and immunosuppression","volume":"217","author":"Pol","year":"2020","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1053\/j.seminoncol.2018.04.001","article-title":"Combining computational and experimental biology to develop therapeutically valuable IL2 muteins","volume":"45","author":"Le\u00f3n","year":"2018","journal-title":"Semin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines13010069","article-title":"Efficacy of anti-cancer immune responses elicited using tumor-targeted IL-2 cytokine and its derivatives in combined preclinical therapies","volume":"13","author":"Balkhi","year":"2025","journal-title":"Vaccines"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-00992-5","article-title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","volume":"22","author":"Bock","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11060-024-04876-z","article-title":"CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws","volume":"171","author":"Sabahi","year":"2025","journal-title":"J Neurooncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S1525","DOI":"10.1016\/j.ymthe.2025.01.035","article-title":"Engineering resilient CAR T cells for immunosuppressive environment","author":"Khalifeh","year":"2025","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13262","article-title":"Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01634-2","article-title":"Cardiotoxic effects following CAR-T cell therapy: A literature review","volume":"27","author":"Joseph","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1494986","article-title":"Influence of CAR T-cell therapy associated complications","volume":"15","author":"Umair","year":"2025","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14737140.2025.2451722","article-title":"Current and emerging treatment options for BRAFV600-mutant melanoma","volume":"25","author":"Javaid","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2024-004327","article-title":"Neurological complications of immune checkpoint inhibitors: a practical guide","volume":"25","author":"Carr","year":"2024","journal-title":"Pract Neurol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1759-7714.15510","article-title":"Immune checkpoint inhibitors +\/\u2013 chemotherapy for patients with NSCLC and brain metastases: A systematic review and network meta-analysis","volume":"16","author":"Brown","year":"2025","journal-title":"Thorac Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1398877","article-title":"Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma","volume":"7","author":"Vermeulen","year":"2018","journal-title":"OncoImmunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24951","article-title":"PD-L1 expression in medulloblastoma: An evaluation by subgroup","volume":"9","author":"Martin","year":"2018","journal-title":"Oncotarget"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.tics.2025.01.004","article-title":"Ignoring the cerebellum is hindering progress in neuroscience","volume":"29","author":"Wang","year":"2025","journal-title":"Trends Cognit Sci"},{"key":"B41","first-page":"122 p","volume-title":"The lateralized cerebellum: insights into motor, cognitive, and affective functioning across ages: a scoping review","author":"Massara","year":"2025"},{"key":"B42","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s00415-025-12967-8","article-title":"Cognition in cerebellar disorders: What\u2019s in the profile? A systematic review and meta-analysis","volume":"272","author":"Reumers","year":"2025","journal-title":"J Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1001\/archneurpsyc.1925.02200140055002","article-title":"Medulloblastoma Cerebelli: a common type of midcerebellar glioma of childhood","volume":"14","author":"Bailey","year":"1925","journal-title":"Arch Neurol Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1177\/0883073815600866","article-title":"Medulloblastoma","volume":"31","author":"Millard","year":"2016","journal-title":"J Child Neurol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.2299","article-title":"Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis","volume":"28","author":"Rutkowski","year":"2010","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.566822","article-title":"Cancer predisposition syndromes and medulloblastoma in the molecular era","volume":"10","author":"Carta","year":"2020","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.2569","article-title":"Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro-Oncology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70289-2","article-title":"Medulloblastoma in childhood: new biological advances","volume":"6","author":"Crawford","year":"2007","journal-title":"Lancet Neurol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-1026","article-title":"Molecular determinants of medulloblastoma metastasis and leptomeningeal dissemination","volume":"19","author":"Li","year":"2021","journal-title":"Mol Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2217\/cns.13.30","article-title":"Medulloblastoma: recurrence and metastasis","volume":"2","author":"Aref","year":"2013","journal-title":"CNS Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-neuro-070815-013838","article-title":"Medulloblastoma: From molecular subgroups to molecular targeted therapies","volume":"41","author":"Wang","year":"2018","journal-title":"Annu Rev Neurosci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1268_22","article-title":"Clinicomorphological and molecular analysis of medulloblastoma and association with survival: A single tertiary care center experience","volume":"19","author":"Badiger","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-019-02102-z","article-title":"Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker","volume":"139","author":"Korshunov","year":"2020","journal-title":"Acta Neuropathol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/1817-1745.22942","article-title":"Medulloblastoma in children: Prognostic factors and predictors of outcome","volume":"1","author":"Menon","year":"2006","journal-title":"J Pediatr Neurosci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12837","article-title":"Pathology, diagnostics, and classification of medulloblastoma","volume":"30","author":"Orr","year":"2020","journal-title":"Brain Pathol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/10935266211018931","article-title":"Medulloblastoma: WHO 2021 and beyond","volume":"25","author":"Cotter","year":"2022","journal-title":"Pediatr Dev Pathol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-031-28202-7_1","article-title":"The world health organization classification of tumors of the central nervous system, fifth edition, 2021: A critical analysis","volume":"46","author":"Miller","year":"2023","journal-title":"Adv Tech Stand Neurosurg"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.ccell.2024.06.002","article-title":"Advancing presurgical non-invasive molecular subgroup prediction in medulloblastoma using artificial intelligence and MRI signatures","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00167","article-title":"Methylation profiling of medulloblastoma in a clinical setting permits sub-classification and reveals new outcome predictions","volume":"11","author":"Alharbi","year":"2020","journal-title":"Front Neurol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12815","article-title":"A CTNNB1-altered medulloblastoma shows the immunophenotypic, DNA methylation and transcriptomic profiles of SHH-activated, and not WNT-activated, medulloblastoma","volume":"48","author":"Chiang","year":"2022","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature11327","article-title":"Subgroup-specific structural variation across 1,000 medulloblastoma genomes","volume":"487","author":"Northcott","year":"2012","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12656","article-title":"The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes","volume":"47","author":"Hicks","year":"2021","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5052","article-title":"Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma","volume":"31","author":"Zhukova","year":"2013","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2176\/nmc.ra.2016-0016","article-title":"Molecular classification of medulloblastoma","volume":"56","author":"Kijima","year":"2016","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15703","article-title":"Molecular stratification of medulloblastoma: clinical outcomes and therapeutic interventions","volume":"42","author":"Sursal","year":"2022","journal-title":"Anticancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1569-6","article-title":"Risk stratification of childhood medulloblastoma in the molecular era: the current consensus","volume":"131","author":"Ramaswamy","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215387","article-title":"Immunotherapy in medulloblastoma: current state of research, challenges, and future perspectives","volume":"13","author":"Voskamp","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.7842","article-title":"Medulloblastoma: from myth to molecular","volume":"35","author":"Ramaswamy","year":"2017","journal-title":"J Clin Oncol"},{"key":"B71","first-page":"472","article-title":"Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc","volume":"130","author":"Friedman","year":"1988","journal-title":"Am J Pathol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","article-title":"Intertumoral heterogeneity within medulloblastoma subgroups","volume":"31","author":"Cavalli","year":"2017","journal-title":"Cancer Cell"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503303321302","article-title":"The molecular basis of Turcot\u2019s syndrome","volume":"332","author":"Hamilton","year":"1995","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.988798","article-title":"Congenital medulloblastoma in two brothers with SUFU-mutated Gorlin-Goltz syndrome: Case reports and literature review","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30242-0","article-title":"Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort","volume":"19","author":"Waszak","year":"2018","journal-title":"Lancet Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s10616-019-00332-3","article-title":"Biological characterization of the UW402, UW473, ONS-76 and DAOY pediatric medulloblastoma cell lines","volume":"71","author":"Bonfim-Silva","year":"2019","journal-title":"Cytotechnology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0063748","article-title":"Medullospheres from DAOY, UW228 and ONS-76 cells: increased stem cell population and proteomic modifications","volume":"8","author":"Zanini","year":"2013","journal-title":"PloS One"},{"key":"B78","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jbiotec.2016.07.028","article-title":"In vitro models of medulloblastoma: Choosing the right tool for the job","volume":"236","author":"Ivanov","year":"2016","journal-title":"J Biotechnol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jprot.2017.03.022","article-title":"Proteomic profiling of isogenic primary and metastatic medulloblastoma cell lines reveals differential expression of key metastatic factors","volume":"160","author":"Gu","year":"2017","journal-title":"J Proteomics"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1186\/2051-5960-2-57","article-title":"Overcoming multiple drug resistance mechanisms in medulloblastoma","volume":"2","author":"Othman","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-198509000-00003","article-title":"Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice","volume":"4","author":"Jacobsen","year":"1985","journal-title":"J Neuropathology Exp Neurol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12964-020-00591-0","article-title":"Phosphoproteomics of short-term hedgehog signaling in human medulloblastoma cells","volume":"18","author":"Scheidt","year":"2020","journal-title":"Cell Commun Signal"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines9091188","article-title":"The role of smoothened-dependent and-independent hedgehog signaling pathway in tumorigenesis","volume":"9","author":"Chai","year":"2021","journal-title":"Biomedicines"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-144","article-title":"Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo","volume":"11","author":"Lee","year":"2011","journal-title":"BMC Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12010226","article-title":"Human medulloblastoma cell lines: Investigating on cancer stem cell-like phenotype","volume":"12","author":"Casciati","year":"2020","journal-title":"Cancers"},{"key":"B86","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/00005072-198511000-00005","article-title":"Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 med","volume":"44","author":"Friedman","year":"1985","journal-title":"J Neuropathology Exp Neurol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-023-02790-2","article-title":"MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma","volume":"42","author":"Pitolli","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30243-7","article-title":"Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study","volume":"18","author":"Schwalbe","year":"2017","journal-title":"Lancet Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02347-7","article-title":"Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling","volume":"142","author":"Nazio","year":"2021","journal-title":"Acta Neuropathologica"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-015-1985-9","article-title":"Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice","volume":"126","author":"Jenkins","year":"2016","journal-title":"J Neuro-Oncology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02530-y","article-title":"A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma","volume":"64","author":"Kling","year":"1991","journal-title":"Lab Invest"},{"key":"B92","first-page":"493","article-title":"Establishment and characterization of four human medulloblastoma-derived cell lines","volume":"7","author":"Keles","year":"1995","journal-title":"Oncol Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/acn3.762","article-title":"Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas","volume":"6","author":"Menyh\u00e1rt","year":"2019","journal-title":"Ann Clin Trans Neurol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-63371-7","article-title":"REST-dependent downregulation of von Hippel-Lindau tumor suppressor promotes autophagy in SHH-medulloblastoma","volume":"14","author":"Singh","year":"2024","journal-title":"Sci Rep"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1042\/BST20150137","article-title":"ABCB1 in children\u2019s brain tumours","volume":"43","author":"Coyle","year":"2015","journal-title":"Biochem Soc Trans"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0485","article-title":"P53 function is compromised by inhibitor 2 of phosphatase 2A in sonic hedgehog medulloblastoma","volume":"17","author":"Wei","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0485","article-title":"Expression of major histocompatibility complex on human medulloblastoma cells with neuronal differentiation","volume":"49","author":"Tamura","year":"1989","journal-title":"Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154111","article-title":"Fenretinide (4-HPR) targets caspase-9, ERK 1\/2 and the wnt3a\/\u03b2-catenin pathway in medulloblastoma cells and medulloblastoma cell spheroids","volume":"11","author":"Bassani","year":"2016","journal-title":"PloS One"},{"key":"B99","doi-asserted-by":"publisher","first-page":"vdae218","DOI":"10.1101\/2024.04.01.587603","article-title":"Sonic hedgehog medulloblastoma cells in co-culture with cerebellar organoids converge towards in vivo Malignant cell states","volume":"7","author":"Van Essen","year":"2024","journal-title":"Neurooncol Adv"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-018-3817-7","article-title":"Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma","volume":"34","author":"Mascaro-Cordeiro","year":"2018","journal-title":"Childs Nerv Syst"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-012-0978-1","article-title":"HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment","volume":"110","author":"Milde","year":"2012","journal-title":"J Neuro-Oncology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-020-01306-4","article-title":"VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells","volume":"3","author":"Penco-Campillo","year":"2020","journal-title":"Commun Biol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0896","article-title":"Combination of ribociclib with BET-Bromodomain and PI3K\/mTOR inhibitors for medulloblastoma treatment in vitro and in vivo","volume":"22","author":"Jonchere","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B104","article-title":"Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts","volume":"64","author":"He","year":"1991","journal-title":"Lab Invest"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms25084416","article-title":"The OTX2 gene induces tumor growth and triggers leptomeningeal metastasis by regulating the mTORC2 signaling pathway in group 3 medulloblastomas","volume":"25","author":"Ampudia-Mesias","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B106","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-025-02281-2","article-title":"3D tumor cultures for drug resistance and screening development in clinical applications","volume":"24","author":"Peng","year":"2025","journal-title":"Mol Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1039\/d4lc00769g","article-title":"Developing 3D bioprinting for organs-on-chips","volume":"25","author":"Wu","year":"2025","journal-title":"Lab Chip"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-024-00960-8","article-title":"A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine","volume":"48","author":"Kalla","year":"2024","journal-title":"Cell Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-2025-128","article-title":"Narrative review of 3D bioprinting for the construction of in vitro tumor models: present and prospects","volume":"14","author":"Tao","year":"2025","journal-title":"Trans Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cpz1.357","article-title":"Establishing an in vitro 3D spheroid model to study medulloblastoma drug response and tumor dissemination","volume":"2","author":"Roper","year":"2022","journal-title":"Curr Protoc"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235972","article-title":"Three-dimensional cell culture systems in pediatric and adult brain tumor precision medicine","volume":"14","author":"Riedel","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14010190","article-title":"3D cell culture models as recapitulators of the tumor microenvironment for the screening of anti-cancer drugs","volume":"14","author":"Barbosa","year":"2022","journal-title":"Cancers"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/path.5591","article-title":"3D hydrogels reveal medulloblastoma subgroup differences and identify extracellular matrix subtypes that predict patient outcome","volume":"253","author":"Linke","year":"2021","journal-title":"J Pathol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1127","article-title":"PGxDB: an interactive web-platform for pharmacogenomics research","volume":"53","author":"Duong Nguyen","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.12.021","article-title":"An animal model of MYC-driven medulloblastoma","volume":"21","author":"Pei","year":"2012","journal-title":"Cancer Cell"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0207-3","article-title":"A biobank of patient-derived pediatric brain tumor models","volume":"24","author":"Brabetz","year":"2018","journal-title":"Nat Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0086-7","article-title":"Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells","volume":"24","author":"Vinci","year":"2018","journal-title":"Nat Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202004776","article-title":"Biomaterials and 3D bioprinting strategies to model glioblastoma and the blood-brain barrier","volume":"33","author":"Tang","year":"2021","journal-title":"Adv Mater"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202501994","article-title":"3D bioprinting models for glioblastoma: from scaffold design to therapeutic application","volume":"37","author":"Branco","year":"2025","journal-title":"Adv Mater"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.620831","article-title":"In vivo and ex vivo pediatric brain tumor models: an overview","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.05.11","article-title":"Paediatric gliomas: diagnosis, molecular biology and management","volume":"6","author":"Blionas","year":"2018","journal-title":"Ann Trans Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12006","article-title":"Development of an early induction model of medulloblastoma in Ptch1 heterozygous mice initiated with N-ethyl-N-nitrosourea","volume":"103","author":"Takahashi","year":"2012","journal-title":"Cancer Sci"},{"key":"B123","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1242\/dmm.009506","article-title":"Bmi1 overexpression in the cerebellar granule cell lineage of mice affects cell proliferation and survival without initiating medulloblastoma formation","volume":"6","author":"Behesti","year":"2013","journal-title":"DMM Dis Models Mech"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.110","article-title":"Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells","volume":"36","author":"Kawauchi","year":"2017","journal-title":"Oncogene"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00832-w","article-title":"Opportunities and challenges for patient-derived models of brain tumors in functional precision medicine","volume":"9","author":"Mann","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02171-5","article-title":"Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource","volume":"140","author":"Smith","year":"2020","journal-title":"Acta Neuropathologica"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091716","article-title":"Direct implantation of patient brain tumor cells into matching locations in mouse brains for patient-derived orthotopic xenograft model development","volume":"16","author":"Qi","year":"2024","journal-title":"Cancers"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae210","article-title":"Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing","volume":"27","author":"van Bree","year":"2025","journal-title":"Neuro Oncol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers16244162","article-title":"DHODH inhibition suppresses MYC and inhibits the growth of medulloblastoma in a novel in vivo zebrafish model","volume":"16","author":"Tsea","year":"2024","journal-title":"Cancers"},{"key":"B131","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature16546","article-title":"Active medulloblastoma enhancers reveal subgroup-specific cellular origins","volume":"530","author":"Lin","year":"2016","journal-title":"Nature"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114559","article-title":"A simple and scalable zebrafish model of Sonic hedgehog medulloblastoma","volume":"43","author":"Casey","year":"2024","journal-title":"Cell Rep"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19424","article-title":"Development of zebrafish medulloblastoma-like PNET model by TALEN-mediated somatic gene inactivation","volume":"8","author":"Shim","year":"2017","journal-title":"Oncotarget"},{"key":"B134","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-1-0716-2788-4_5","article-title":"Evaluation of antitumor and on-target activity of HDAC inhibitors with the zebrafish embryo xenograft model","volume":"2589","author":"Gatzweiler","year":"2023","journal-title":"Methods Mol Biol (Clifton NJ)"},{"key":"B135","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jaut.2019.01.011","article-title":"Primary immunodeficiency and autoimmunity: A comprehensive review","volume":"99","author":"Amaya-Uribe","year":"2019","journal-title":"J Autoimmun"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.07.010","article-title":"The mechanisms of T cell selection in the thymus","volume":"38","author":"Takaba","year":"2017","journal-title":"Trends Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-012-8345-8","article-title":"Tolerance and autoimmunity in primary immunodeficiency disease: A comprehensive review","volume":"45","author":"Gupta","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/16078454.2024.2366718","article-title":"Future directions in haploidentical hematopoietic stem cell transplantation","volume":"29","author":"Vittayawacharin","year":"2024","journal-title":"Hematol (United Kingdom)"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.821533","article-title":"KIR in allogeneic hematopoietic stem cell transplantation: need for a unified paradigm for donor selection","volume":"13","author":"Dhuyser","year":"2022","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00105","article-title":"TLR\/NCR\/KIR: Which one to use and when","volume":"5","author":"Sivori","year":"2014","journal-title":"Front Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.359","article-title":"NK cell receptors","volume":"16","author":"Lanier","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omto.2021.11.016","article-title":"Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges","volume":"24","author":"Poggi","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac236","article-title":"Cellular immunotherapy for medulloblastoma","volume":"25","author":"Schakelaar","year":"2023","journal-title":"Neuro-Oncology"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26754","article-title":"A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma","volume":"65","author":"Kramer","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.679852","article-title":"Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3","volume":"290","author":"Ahmed","year":"2015","journal-title":"J Biol Chem"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0715","article-title":"Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605375","article-title":"Clinical importance of B7-H3 expression in human pancreatic cancer","volume":"101","author":"Yamato","year":"2009","journal-title":"Br J Cancer"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c02850","article-title":"Multivalent, bispecific \u03b1b7-H3-\u03b1CD3 chemically self-assembled nanorings direct potent T cell responses against medulloblastoma","volume":"16","author":"Mews","year":"2022","journal-title":"ACS Nano"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-01024-8","article-title":"Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.aax3160","article-title":"B7-H3\u00d74-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes","volume":"7","author":"You","year":"2021","journal-title":"Sci Adv"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical development of MGC018, a duocarmycin-based antibody\u2013drug conjugate targeting B7-H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0554","article-title":"DS-7300a, a DNA topoisomerase I inhibitor, DXd-based antibody-drug conjugate targeting B7-H3, exerts potent antitumor activities in preclinical models","volume":"21","author":"Yamato","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B153","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","article-title":"Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature","volume":"31","author":"Seaman","year":"2017","journal-title":"Cancer Cell"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom12121744","article-title":"Evaluation of B7-H3 targeted immunotherapy in a 3D organoid model of craniopharyngioma","volume":"12","author":"Tang","year":"2022","journal-title":"Biomolecules"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-013-2290-6","article-title":"Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells","volume":"29","author":"Jaeger","year":"2013","journal-title":"Child\u2019s Nervous System"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad205","article-title":"Systematic characterization of antibody\u2013drug conjugate targets in central nervous system tumors","volume":"26","author":"Coy","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27919","article-title":"Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of Malignant brain tumors","volume":"132","author":"Chandramohan","year":"2013","journal-title":"Int J Cancer"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2968","article-title":"Disrupting the CD47-SIRP\u03b1 anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for Malignant pediatric brain tumors","volume":"9","author":"Gholamin","year":"2017","journal-title":"Sci Transl Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29031","article-title":"Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial","volume":"68","author":"Levy","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S458278","article-title":"Deciphering Natural Killer Cell Cytotoxicity Against Medulloblastoma in vitro and in vivo: Implications for Immunotherapy","volume":"13","author":"Gauthier","year":"2024","journal-title":"ImmunoTargets Ther"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737546","article-title":"Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity","volume":"37","author":"Castriconi","year":"2007","journal-title":"Eur J Immunol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00094","article-title":"In vitro natural killer cell immunotherapy for medulloblastoma","volume":"3","author":"Fern\u00e1ndez","year":"2013","journal-title":"Front Oncol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11307-024-01969-z","article-title":"Preclinical and Clinical-Scale Magnetic Particle Imaging of Natural Killer Cells: in vitro and ex vivo Demonstration of Cellular Sensitivity, Resolution, and Quantification","volume":"27","author":"Sehl","year":"2024","journal-title":"Mol Imaging Biol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2007.00896.x","article-title":"Successful isolation and long-term establishment of a cell line with stem cell-like features from an anaplastic medulloblastoma","volume":"34","author":"Raso","year":"2008","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4735","article-title":"Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma","volume":"67","author":"Raffaghello","year":"2007","journal-title":"Cancer Res"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-7-59","article-title":"A novel role of HLA class I in the pathology of medulloblastoma","volume":"7","author":"Smith","year":"2009","journal-title":"J Trans Med"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1643","article-title":"ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors","volume":"75","author":"Cifaldi","year":"2015","journal-title":"Cancer Res"},{"key":"B168","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11060-019-03162-7","article-title":"Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI (Journal of Neuro-Oncology, (2019), 142, 3, (395-407), 10.1007\/s11060-019-03091-5)","volume":"142","author":"Kennis","year":"2019","journal-title":"J Neuro-Oncology"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-02651-y","article-title":"Notch signaling and natural killer cell infiltration in tumor tissues underlie medulloblastoma prognosis","volume":"11","author":"Liang","year":"2021","journal-title":"Sci Rep"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-023-00839-2","article-title":"Medulloblastoma and high-grade glioma organoids for drug screening, lineage tracing, co-culture and in vivo assay","volume":"18","author":"Lago","year":"2023","journal-title":"Nat Protoc"},{"key":"B171","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1101\/gad.351936.124","article-title":"Arrested development: the dysfunctional life history of medulloblastoma","volume":"39","author":"Tao","year":"2024","journal-title":"Genes Dev"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152629","article-title":"VISTA emerges as a promising target against immune evasion mechanisms in medulloblastoma","volume":"16","author":"Mu\u00f1oz Perez","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B173","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clim.2013.06.005","article-title":"Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells","volume":"149","author":"Liu","year":"2013","journal-title":"Clin Immunol"},{"key":"B174","first-page":"1970","article-title":"Abstract 1790: Exploring the efficacy of allogeneic gamma delta T cell adoptive cell therapy against the pediatric brain tumor medulloblastoma","year":"2023","journal-title":"Advancing Front Cancer Sci Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2485535","article-title":"EphA2 and phosphoantigen-mediated selective killing of medulloblastoma by \u03b3\u03b4T cells preserves neuronal and stem cell integrity","volume":"14","author":"Boutin","year":"2025","journal-title":"Oncoimmunology"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005660","article-title":"Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab","volume":"10","author":"Benelli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B177","first-page":"Abstract nr 1790","article-title":"Exploring the efficacy of allogeneic gamma delta T cell adoptive cell therapy against the pediatric brain tumor medulloblastoma","author":"Lowry","year":"2023"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1498431","article-title":"DNA vaccines as promising immuno-therapeutics against cancer: a new insight","volume":"15","author":"Shariati","year":"2024","journal-title":"Front Immunol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"32","author":"Jayathilaka","year":"2024","journal-title":"Br J Cancer"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04881-2","article-title":"Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions","volume":"171","author":"Badani","year":"2024","journal-title":"J Neuro-Oncology"},{"key":"B181","doi-asserted-by":"publisher","first-page":"102506","DOI":"10.1016\/j.coi.2024.102506","article-title":"Functional subsets of tumor-specific CD8+ T cells in draining lymph nodes and tumor microenvironment","volume":"93","author":"Huang","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4236","article-title":"Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis","volume":"10","author":"Ouyang","year":"2021","journal-title":"Cancer Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1200\/GO-24-00409","article-title":"Overcoming financial and access barriers in global cancer care with low-dose immunotherapy: A systematic review","volume":"11","author":"Hoyek","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-024-01363-y","article-title":"Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma","volume":"16","author":"Yang","year":"2024","journal-title":"Genome Med"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.14.1.333","article-title":"On immunological memory","volume":"14","author":"Zinkernagel","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-024-01281-z","article-title":"mRNA-based precision targeting of neoantigens and tumor-associated antigens in Malignant brain tumors","volume":"16","author":"Trivedi","year":"2024","journal-title":"Genome Med"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.06.009","article-title":"Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy","volume":"21","author":"Blaeschke","year":"2019","journal-title":"Cytotherapy"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225838","article-title":"Identification of an immunogenic medulloblastoma-specific fusion 1420 involving EPC2 and GULP1","volume":"13","author":"Paret","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-26936-y","article-title":"Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors","volume":"12","author":"Rivero-Hinojosa","year":"2021","journal-title":"Nat Commun"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0172552","article-title":"Uniformity under in vitro conditions: Changes in the phenotype of cancer cell lines derived from different medulloblastoma subgroups","volume":"12","author":"Chlapek","year":"2017","journal-title":"PloS One"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6195","article-title":"Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes","volume":"6","author":"Liang","year":"2015","journal-title":"Oncotarget"},{"key":"B192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0235852","article-title":"Astrocytes influence medulloblastoma phenotypes and CD133 surface expression","volume":"15","author":"Gronseth","year":"2020","journal-title":"PloS One"},{"key":"B193","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26508\/LSA.202201380","article-title":"Spatial proteomics finds CD155 and Endophilin-A1 as mediators of growth and invasion in medulloblastoma","volume":"5","author":"Capdeville","year":"2022","journal-title":"Life Sci Alliance"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov123","article-title":"Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses","volume":"18","author":"Friedman","year":"2016","journal-title":"Neuro-Oncology"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-015-1758-5","article-title":"Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas","volume":"123","author":"Sand\u00e9n","year":"2015","journal-title":"J Neuro-Oncology"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1880","article-title":"GD2-targeting CAR T-cell therapy for patients with GD2+ Medulloblastoma","volume":"30","author":"Ciccone","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14246051","article-title":"GD2 expression in medulloblastoma and neuroblastoma for personalized immunotherapy: A matter of subtype","volume":"14","author":"Paret","year":"2022","journal-title":"Cancers"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.08.010","article-title":"Multiomic medulloblastomas","volume":"34","author":"Rahmann","year":"2018","journal-title":"Cancer Cell"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01424-X","article-title":"Medulloblastoma: signalling a change in treatment","volume":"5","author":"Gilbertson","year":"2004","journal-title":"Lancet Oncol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00944-9","article-title":"Targeting ephA2 in cancer","volume":"13","author":"Xiao","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-282X2008000300020","article-title":"Immunohistochemical expression of markers KI-67, NeuN, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters","volume":"66","author":"Meurer","year":"2008","journal-title":"Arquivos Neuro-Psiquiatria"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1159\/000316640","article-title":"Expression of epidermal growth factor receptor and HER-2 in pediatric embryonal brain tumors","volume":"46","author":"Patereli","year":"2010","journal-title":"Pediatr Neurosurg"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B204","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mco2.70020","article-title":"Metastatic brain tumors: from development to cutting-edge treatment","volume":"6","author":"Tanzhu","year":"2025","journal-title":"MedComm"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114890","article-title":"B7-H3 immunoregulatory roles in cancer","volume":"163","author":"Mortezaee","year":"2023","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.85813","article-title":"B7-H3 in brain Malignancies: immunology and immunotherapy","volume":"19","author":"Guo","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B207","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.29316","article-title":"Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma","volume":"69","author":"Varlet","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00905-6","article-title":"FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy","volume":"6","author":"Ni","year":"2025","journal-title":"Nat Cancer"},{"key":"B209","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-024-00679-6","article-title":"Advances in CAR-T therapy for central nervous system tumors","volume":"12","author":"Zhou","year":"2024","journal-title":"biomark Res"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01093-7","article-title":"From TCR fundamental research to innovative chimeric antigen receptor design","volume":"25","author":"Minguet","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers17020282","article-title":"Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic Malignancies","volume":"17","author":"Bangolo","year":"2025","journal-title":"Cancers"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-016-3305-x","article-title":"Immunological low-dose radiation modulates the pediatric medulloblastoma antigens and enhances antibody-dependent cellular cytotoxicity","volume":"33","author":"Das","year":"2017","journal-title":"Child\u2019s Nervous System"},{"key":"B213","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1186\/s13045-025-01677-3","article-title":"CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting","volume":"18","author":"Kong","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1511931","article-title":"Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy","volume":"12","author":"Dehghan","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305","article-title":"Engineered CAR-macrophages as adoptive immunotherapies for solid tumors","volume":"12","author":"Sloas","year":"2021","journal-title":"Front Immunol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70726","article-title":"CAR-T cell manufacturing for hematological and solid tumors: from the preclinical to clinical point of view","volume":"14","author":"Capolla","year":"2025","journal-title":"Cancer Med"},{"key":"B219","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40272-024-00653-7","article-title":"Developing CAR T-cell therapies for pediatric solid tumors","volume":"27","author":"Canciani","year":"2024","journal-title":"Paediatric Drugs"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.817296","article-title":"CAR T cell therapy in primary brain tumors: current investigations and the future","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1124\/mol.107.042986","article-title":"Revoking the privilege: targeting HER2 in the central nervous system","volume":"73","author":"Contessa","year":"2008","journal-title":"Mol Pharmacol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2917-2","article-title":"Rethinking medulloblastoma from a targeted therapeutics perspective","volume":"139","author":"Hashimoto","year":"2018","journal-title":"J Neuro-Oncology"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.10163","article-title":"Dual inhibitor AEE788 reduces tumor growth in preclinical models of medulloblastoma","volume":"3","author":"Meco","year":"2010","journal-title":"Trans Oncol"},{"key":"B225","article-title":"Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma","volume":"57","author":"Gilbertson","year":"1997","journal-title":"Cancer Res"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024929522376","article-title":"Co-expression of ErbB-family members in human breast cancer: Her-2\/neu is the preferred dimerization candidate in nodal-positive tumors","volume":"80","author":"Hudelist","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"B227","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0340-z","article-title":"Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells","volume":"6","author":"Nellan","year":"2018","journal-title":"J ImmunoTherapy Cancer"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4309","article-title":"Regression of experimental medulloblastoma following transfer of HER2-specific T cells","volume":"67","author":"Ahmed","year":"2007","journal-title":"Cancer Res"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1177\/1066896913492196","article-title":"C-erbB2\/HER2 in human gliomas, medulloblastomas, and meningiomas: A minireview","volume":"21","author":"Waage","year":"2013","journal-title":"Int J Surg Pathol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-095","article-title":"Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects","volume":"11","author":"Meco","year":"2009","journal-title":"vivo. Neuro-Oncology"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-007-9467-3","article-title":"Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: An in vitro evaluation using human cell lines","volume":"86","author":"Bernardi","year":"2008","journal-title":"J Neuro-Oncology"},{"key":"B232","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00401-004-0959-3","article-title":"Prognosis-related histomorphological and immunohistochemical markers in central nervous system tumors of childhood and adolescence","volume":"109","author":"Rickert","year":"2005","journal-title":"Acta Neuropathol"},{"key":"B233","article-title":"Epidermal growth factor receptor (EGFR) expression in childhood brain tumors","volume":"19","author":"Bodey","year":"2005","journal-title":"In Vivo"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat Med"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20470","article-title":"Analysis of interleukin-13 receptor \u03b12 expression in human pediatric brain tumors","volume":"101","author":"Kawakami","year":"2004","journal-title":"Cancer"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188802","article-title":"Interleukin 13 receptor alpha 2 (IL13R\u03b12): Expression, signaling pathways and therapeutic applications in cancer","volume":"1877","author":"Ja\u00e9n","year":"2022","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"key":"B237","doi-asserted-by":"publisher","first-page":"53","DOI":"10.36401\/JIPO-23-18","article-title":"B7-H3 inhibitors in oncology clinical trials: A review","volume":"7","author":"Feustel","year":"2024","journal-title":"J Immunotherapy Precis Oncol"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701006","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: An attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104648","article-title":"CAR T-cell therapy landscape in pediatric, adolescent and young adult oncology \u2013 A comprehensive analysis of clinical trials","volume":"209","author":"Mart\u00ednez-Gamboa","year":"2025","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081158","article-title":"Role of MYC-miR-29-B7-H3 in medulloblastoma growth and angiogenesis","volume":"8","author":"Purvis","year":"2019","journal-title":"J Clin Med"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12829","article-title":"MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3)","volume":"30","author":"Kanchan","year":"2020","journal-title":"Brain Pathol"},{"key":"B244","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol Cancer"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02762-y","article-title":"Pediatric medulloblastoma express immune checkpoint B7-H3","volume":"24","author":"Li","year":"2022","journal-title":"Clin Trans Oncol"},{"key":"B246","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21197050","article-title":"B7-h3 in medulloblastoma-derived exosomes; a novel tumorigenic role","volume":"21","author":"Purvis","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.12.6294","article-title":"Characterization of mouse and human B7-H3 genes","volume":"168","author":"Sun","year":"2002","journal-title":"J Immunol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041731","article-title":"Identification of the B7-H3 interaction partners using a proximity labeling strategy","volume":"26","author":"Liao","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M113.031591","article-title":"Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ","volume":"13","author":"Cox","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.TIR119.001433","article-title":"A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3\/CD276 and PVR\/CD155","volume":"18","author":"Husain","year":"2019","journal-title":"Mol Cell Proteomics"},{"key":"B252","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1073\/pnas.2025451118","article-title":"A membrane protein display platform for receptor interactome discovery","volume":"118","author":"Cao","year":"2021","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B253","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/noajnl\/vdac098","article-title":"Neuro-oncology advances","volume":"4","author":"Ciprut","year":"2022","journal-title":"Neuro-Oncology Advances"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0802423105","article-title":"Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses","volume":"105","author":"Hashiguchi","year":"2008","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205009","article-title":"The tumor microenvironment of medulloblastoma: an intricate multicellular network with therapeutic potential","volume":"14","author":"van Bree","year":"2022","journal-title":"Cancers"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox033","article-title":"The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival","volume":"19","author":"Thompson","year":"2017","journal-title":"Neuro-Oncology"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.12.006","article-title":"C-Myc enhances colon cancer cell-mediated angiogenesis through the regulation of HIF-1\u03b1","volume":"430","author":"Chen","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1038\/ng1855","article-title":"Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster","volume":"38","author":"Dews","year":"2006","journal-title":"Nat Genet"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.46","article-title":"MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours","volume":"114","author":"Green","year":"2016","journal-title":"Br J Cancer"},{"key":"B260","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1078-2","article-title":"MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma","volume":"38","author":"Chen","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B261","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21207710","article-title":"Myc as a multifaceted regulator of tumor microenvironment leading to metastasis","volume":"21","author":"Me\u0161kyt\u0117","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp078126","article-title":"Pluripotency redux\u2013advances in stem-cell research","volume":"357","author":"Gearhart","year":"2007","journal-title":"N Engl J Med"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01761-7","article-title":"Targeting protein synthesis pathways in MYC-amplified medulloblastoma","volume":"16","author":"Kumar","year":"2025","journal-title":"Discover Oncol"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-00981-1","article-title":"Targeting angiogenic factors for the treatment of medulloblastoma","volume":"23","author":"Saker","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(01)00225-8","article-title":"Angiogenic profile of childhood primitive neuroectodermal brain tumours\/medulloblastomas","volume":"37","author":"Huber","year":"2001","journal-title":"Eur J Cancer"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-012-2013-4","article-title":"Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: A multi-institutional experience","volume":"29","author":"Aguilera","year":"2013","journal-title":"Child\u2019s Nervous System"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4437","article-title":"Sustained survival benefit in recurrent medulloblastoma by a metronomic antiangiogenic regimen: A nonrandomized controlled trial","volume":"9","author":"Peyrl","year":"2023","journal-title":"JAMA Oncol"},{"key":"B268","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/neuonc\/nox119","article-title":"Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha","volume":"20","author":"Olmez","year":"2018","journal-title":"Neuro Oncol"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.964973","article-title":"Podoplanin: Its roles and functions in neurological diseases and brain cancers","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B270","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jtumed.2024.11.007","article-title":"Podoplanin expression in various types of oral dysplasia and oral squamous cell carcinoma","volume":"20","author":"Mashhadiabbas","year":"2024","journal-title":"J Taibah Univ Med Sci"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.178427","article-title":"Role of podoplanin in potentially Malignant disorders and oral squamous cell carcinoma and its correlation with lymphangiogenesis","volume":"52","author":"Parhar","year":"2015","journal-title":"Indian J Cancer"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.060790","article-title":"The platelet aggregation-inducing factor aggrus\/podoplanin promotes pulmonary metastasis","volume":"170","author":"Kunita","year":"2007","journal-title":"Am J Pathol"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.03.010","article-title":"Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton","volume":"9","author":"Wicki","year":"2006","journal-title":"Cancer Cell"},{"key":"B274","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1349-7006.2007.00634.x","article-title":"Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2","volume":"99","author":"Kato","year":"2008","journal-title":"Cancer Sci"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00283","article-title":"Podoplanin: emerging functions in development, the immune system, and cancer","author":"Astarita","year":"2012","journal-title":"Front Immunol"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S366620","article-title":"The role of podoplanin in the immune system and inflammation","volume":"15","author":"Zhang","year":"2022","journal-title":"J Inflammation Res"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0060","article-title":"CAR T cells targeting Podoplanin reduce orthotopic glioblastomas in mouse brains","volume":"4","author":"Shiina","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00262","article-title":"How to hit mesenchymal stromal cells and make the tumor microenvironment immunostimulant rather than immunosuppressive","volume":"9","author":"Poggi","year":"2018","journal-title":"Front Immunol"},{"key":"B279","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines4040041","article-title":"Mesenchymal stromal cells can regulate the immune response in the tumor microenvironment","volume":"4","author":"Poggi","year":"2016","journal-title":"Vaccines"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01150","article-title":"Targeting the epidermal growth factor receptor can counteract the inhibition of natural killer cell function exerted by colorectal tumor-associated fibroblasts","volume":"9","author":"Costa","year":"2018","journal-title":"Front Immunol"},{"key":"B281","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41568-024-00761-z","article-title":"Convergent inducers and effectors of T cell paralysis in the tumour microenvironment","volume":"25","author":"Hanahan","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B282","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-13764-3","article-title":"Role of CD47 in tumor immunity: a potential target for combination therapy","volume":"12","author":"Huang","year":"2022","journal-title":"Sci Rep"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005871","article-title":"Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammat","volume":"11","author":"Marquardt","year":"2023","journal-title":"J ImmunoTherapy Cancer"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1062856","article-title":"Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets","volume":"14","author":"Marques","year":"2023","journal-title":"Front Immunol"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6227","article-title":"miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.4324","article-title":"Medulloblastoma comprises four distinct molecular variants","volume":"29","author":"Northcott","year":"2011","journal-title":"J Clin Oncol"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2332","article-title":"Engineering macrophages to phagocytose cancer cells by blocking the CD47\/SIRP\u0251 axis","volume":"8","author":"Yang","year":"2019","journal-title":"Cancer Med"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02989-2","article-title":"Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody","volume":"71","author":"Ni","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.10.013","article-title":"The mystery and magic of glia: a perspective on their roles in health and disease","volume":"60","author":"Barres","year":"2008","journal-title":"Neuron"},{"key":"B290","doi-asserted-by":"publisher","DOI":"10.1177\/1073858418809941","article-title":"Astrocytes: heterogeneous and dynamic phenotypes in neurodegeneration and innate immunity","volume":"25","author":"Cunningham","year":"2019","journal-title":"Neuroscientist"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021021","article-title":"Comparative transcriptomic analysis of cerebellar astrocytes across developmental stages and brain regions","volume":"25","author":"Kwon","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B292","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/s41392-023-01628-9","article-title":"Astrocytes in human central nervous system diseases: a frontier for new therapies","volume":"8","author":"Verkhratsky","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23467","article-title":"Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes","volume":"66","author":"Neal","year":"2018","journal-title":"Glia"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.07.004","article-title":"Astrocyte reactivity: subtypes, states, and functions in CNS innate immunity","volume":"41","author":"Sofroniew","year":"2020","journal-title":"Trends Immunol"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-025-01878-6","article-title":"Astrocyte heterogeneity reveals region-specific astrogenesis in the white matter","volume":"28","author":"Bocchi","year":"2025","journal-title":"Nat Neurosci"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.1126\/science.adc9020","article-title":"Molecular basis of astrocyte diversity and morphology across the CNS in health and disease","volume":"378","author":"Endo","year":"2022","journal-title":"Science"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.3390\/biom11091361","article-title":"Beyond the GFAP-astrocyte protein markers in the brain","volume":"11","author":"Jurga","year":"2021","journal-title":"Biomolecules"},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1463","article-title":"Astrocytes promote medulloblastoma progression through hedgehog secretion","volume":"77","author":"Liu","year":"2017","journal-title":"Cancer Res"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28040267","article-title":"Decoding the roles of astrocytes and hedgehog signaling in medulloblastoma","volume":"28","author":"Duarte","year":"2021","journal-title":"Curr Oncol"},{"key":"B301","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-020-0443-2","article-title":"Sustained hedgehog signaling in medulloblastoma tumoroids is attributed to stromal astrocytes and astrocyte-derived extracellular matrix","volume":"100","author":"Cheng","year":"2020","journal-title":"Lab Invest"},{"key":"B302","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1084\/jem.20211141","article-title":"A SHHecret target of relapsed medulloblastoma: Astrocytes","volume":"218","author":"Qadeer","year":"2021","journal-title":"J Exp Med"},{"key":"B303","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bpa.13212","article-title":"Tumor-associated astrocytes promote tumor progression of Sonic Hedgehog medulloblastoma by secreting lipocalin-2","volume":"34","author":"Li","year":"2024","journal-title":"Brain Pathol"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz214","article-title":"Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion","volume":"22","author":"Liu","year":"2020","journal-title":"Neuro-Oncology"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa057","article-title":"Astrocytes: New stars in the medulloblastoma firmament","volume":"22","author":"Eberhart","year":"2020","journal-title":"Neuro-Oncology"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae178","article-title":"Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study","volume":"27","author":"Schwalbe","year":"2025","journal-title":"Neuro Oncol"},{"key":"B307","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-022-02522-4","article-title":"Identification of low and very high-risk patients with non-WNT\/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts","volume":"145","author":"Mynarek","year":"2023","journal-title":"Acta Neuropathol"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1016\/j.phoj.2023.05.001","article-title":"Review of the impact of molecular analysis on the therapy of medulloblastoma","volume":"8","author":"Sarvode","year":"2023","journal-title":"Pediatr Hematol Oncol J"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02459-y","article-title":"Adjuvant and neo-adjuvant therapy for non-small cell lung cancer without EGFR mutations or ALK rearrangements","volume":"30","author":"Takenaka","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad031","article-title":"Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS Malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908","volume":"25","author":"Dunkel","year":"2023","journal-title":"Neuro Oncol"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001339","article-title":"Nivolumab in the treatment of recurrent or refractory pediatric brain tumors: A single institutional experience","volume":"41","author":"Gorsi","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"B312","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2018.1462430","article-title":"Subgroup-specific immune and stromal microenvironment in medulloblastoma","volume":"7","author":"Bockmayr","year":"2018","journal-title":"OncoImmunology"},{"key":"B313","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00429","article-title":"Construction and validation of a 13-gene signature for prognosis prediction in medulloblastoma","volume":"11","author":"Li","year":"2020","journal-title":"Front Genet"},{"key":"B314","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3892\/ol.2020.12260","article-title":"Immune cell infiltration and cytokine secretion analysis reveal a non-inflammatory microenvironment of medulloblastoma","volume":"20","author":"Diao","year":"2020","journal-title":"Oncol Lett"},{"key":"B315","doi-asserted-by":"publisher","DOI":"10.3171\/2016.11.JNS16991","article-title":"High programmed cell death 1 ligand-1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma","volume":"128","author":"Murata","year":"2018","journal-title":"J Neurosurg"},{"key":"B316","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18070-y","article-title":"Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity","volume":"11","author":"Grabovska","year":"2020","journal-title":"Nat Commun"},{"key":"B317","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30724","article-title":"Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues","volume":"123","author":"Majzner","year":"2017","journal-title":"Cancer"},{"key":"B318","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41467-025-56268-0","article-title":"Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics","volume":"16","author":"Velz","year":"2025","journal-title":"Nat Commun"},{"key":"B319","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41698-024-00570-5","article-title":"Pan-cancer evaluation of regulated cell death to predict overall survival and immune checkpoint inhibitor response","volume":"8","author":"Zhang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B320","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70196","article-title":"Immune checkpoint molecules: A review on pathways and immunotherapy implications","volume":"13","author":"Rezazadeh-Gavgani","year":"2025","journal-title":"Immun Inflammation Dis"},{"key":"B321","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102614","article-title":"Novel targets for immune-checkpoint inhibition in cancer","volume":"120","author":"Borgeaud","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B322","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13699","article-title":"Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors","volume":"19","author":"Hern\u00e1ndez-Prat","year":"2025","journal-title":"Mol Oncol"},{"key":"B323","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ccell.2025.02.014","article-title":"Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy","volume":"43","author":"Song","year":"2025","journal-title":"Cancer Cell"},{"key":"B324","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41467-024-54861-3","article-title":"Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"B325","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1129434","article-title":"Biological functions of the Olig gene family in brain cancer and therapeutic targeting","volume":"17","author":"Szu","year":"2023","journal-title":"Front Neurosci"},{"key":"B326","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506535102","article-title":"Expression pattern of the transcription factor Olig2 in response to brain injuries: Implications for neuronal repair","volume":"102","author":"Buffo","year":"2005","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B327","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3386","article-title":"Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2","volume":"13","author":"Meijer","year":"2012","journal-title":"Nat Rev Neurosci"},{"key":"B328","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s0092-8674(02)00677-3","article-title":"The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification","volume":"109","author":"Zhou","year":"2002","journal-title":"Cell"},{"key":"B329","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.011","article-title":"Early rhombic lip Protogenin+ve stem cells in a human-specific neurovascular niche initiate and maintain group 3 medulloblastoma","volume":"187","author":"Visvanathan","year":"2024","journal-title":"Cell"},{"key":"B330","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15646","article-title":"Chemotherapy can synergize with adoptive immunotherapy to inhibit medulloblastoma growth","volume":"42","author":"Lasky","year":"2022","journal-title":"Anticancer Res"},{"key":"B331","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.044","article-title":"Integrated proteogenomic characterization across major histological types of pediatric brain cancer","volume":"183","author":"Petralia","year":"2020","journal-title":"Cell"},{"key":"B332","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2112","journal-title":"Cancer Discovery"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1602930\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:27:54Z","timestamp":1751520474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1602930\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":332,"alternative-id":["10.3389\/fimmu.2025.1602930"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1602930","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"article-number":"1602930"}}